Last reviewed · How we verify
GLUCOSAMINE
Glucosamine, a marketed drug, stimulates the production of glycosaminoglycans, essential for cartilage health, and faces competition from off-patent drugs like nabumetone. Its key strength lies in its well-established mechanism of action and ongoing market presence despite the lack of a primary indication specified. The primary risk is the key composition patent expiry in 2028, which could lead to increased generic competition.
At a glance
| Generic name | GLUCOSAMINE |
|---|---|
| Drug class | glucosamine |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Kinesiological / Dietary Supplement Intervention in Knee Osteoarthritis (NA)
- Oral N-acetylglucosamine in Crohn's Disease (PHASE2)
- A Clinical Study to Evaluate the Efficacy of Native CT-II® in Individuals With Knee Osteoarthritis (NA)
- Effects of UC-II, Glucosamine and Curcumin Supplementation on Knee Pain and Inflammation. (NA)
- Long-Term Effects of Mobithron Advance on Knee Osteoarthritis Aims to Investigate the Effects of Mobithron Advance on OA Progression (EARLY_PHASE1)
- Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. (PHASE2,PHASE3)
- Understanding the Role of Doulas in Supporting People With PMADs (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLUCOSAMINE CI brief — competitive landscape report
- GLUCOSAMINE updates RSS · CI watch RSS